Cite
HARVARD Citation
Chau, I. et al. (2017). Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European journal of cancer. pp. 17-25. [Online].